Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Wednesday 27 March, 2002

Xenova Group PLC

Research Update

Xenova Group PLC
27 March 2002

                                Xenova Group plc

      Successful Results of Phase IIa Trial for Therapeutic Vaccine TA-HPV

Slough, UK, 27 March, 2002 - Xenova Group plc (Nasdaq NM: XNVA; London Stock
Exchange: XEN) announces the publication of results from a physician-initiated
Phase IIa trial of Xenova's TA-HPV therapeutic vaccine at the meeting of the
British Society of Investigative Dermatology, held this week in Norwich, UK.

Results of the trial, which was carried out by researchers at Addenbrooke's
Hospital, Cambridge, UK, in a total of 12 women with high grade human
papillomavirus (HPV) positive ano-genital intraepithelial neoplasia (AGIN) of up
to 15 years' duration, showed the vaccine to be safe and well tolerated.  Five
(42%) of the patients showed at least a 50% reduction in total lesion diameter
over 24 weeks, of whom one patient showed complete regression of her lesion.
Overall, there was an average decrease in lesion size of 40% with 83% of women
showing some improvement. Results of the study indicate that this vaccine may
have an effect on HPV-positive AGIN and suggest that further studies are
warranted.  These results are consistent with data announced in October 2001
from a similar Phase IIa study involving 18 patients conducted at St Mary's
Hospital, Manchester, UK.

AGIN is a chronic disorder associated with high risk genital HPVs and is
frequently multifocal, with recurrence common after surgical excision.   There
is a high risk of progression to invasive malignancy in the form of ano-genital
cancers, such as vulval cancer.

TA-HPV is a vaccine containing certain disease-associated HPV genes inserted
into a carrier vaccinia virus vector. TA-HPV is currently undergoing an
open-label, physician-sponsored Phase II 'Prime-Boost' clinical trial in
conjunction with a further Xenova vaccine, TA-CIN.  Results of this 
'Prime-Boost' trial, which is being carried out in up to 30 women at 3 centres 
in the UK, are expected in the second half of 2002.

David Oxlade, Chief Executive Officer of Xenova, commented:

'The results of this study are highly encouraging, and support the results of a
previous Phase IIa study announced last year, which showed complete or partial
response in a similar percentage of patients.  AGIN conditions are highly
recurrent, difficult to treat and have debilitating effects for sufferers.  The
results of the 'Prime-Boost' trial will provide us with an indication of the
best development route for both our TA-HPV and TA-CIN vaccines.'



UK:                                                  US:

Xenova Group plc                                  Trout Group/BMC Communications
Tel: +44 (0)1753 706600                           Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer           Press: Brad Miles (Ext 17) 
Daniel Abrams, Group Finance Director             Lauren Tortorete (Ext 20) 
Hilary Reid Evans, Corporate Communications       Investors: Jonathan Fassberg 
                                                  (Ext 16) Lee Stern (Ext 22)

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Fiona Noblet

                                Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova currently has a broad pipeline of
eight products in clinical development.  Xenova's lead programme is a
P-glycoprotein antagonist for the treatment of multi-drug resistance in cancer,
known as tariquidar or XR9576.  Tariquidar has completed a successful series of
three Phase IIa clinical trials and is expected to enter Phase III clinical
development in the first half of 2002.  Tariquidar was partnered for the North
American market with QLT Inc in August 2001. The Group has a well-established
track record in the identification, development and partnering of innovative
products and technologies and has partnerships with other major pharmaceutical
companies including Lilly, Pfizer, Celltech and Millennium Pharmaceuticals.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialisation of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialisation activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange